Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MDM2 | Q00987 | 1/20 | 1.00 |
| ▸ | NCOA1 | Q15788 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CDA | P32320 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine SCHEMBL787927 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL12202579 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL329878 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL172274 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14644972 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL17993618 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14853684 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL20546595 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL15630291 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230399354-A1 | PREPARATION METHOD OF 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDE | BEIJING RIBIO PHARMA CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2023228177-A1 | COMPOSITIONS COMPRISING ASPACYTARABINE AND ADDITIONAL COMPOUNDS, AND USE THEREOF | BIOSIGHT LTD. (IL) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| WO-2023138079-A1 | PREPARATION METHOD FOR 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDE | 北京瑞博奥医药科技有限公司 | 2023-07-27 | — | — | WO | disclosed |
| EP-3512486-B2 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2023-07-12 | — | — | EP | disclosed |
| US-20230174660-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER | IGM BIOSCIENCES, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2009-08-20 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090131351-A1 | Methods, compositions, and kits for modulating tumor cell proliferation | ANTISOMA RESEARCH LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7524831-B2 | Treatments for Flaviviridae virus infection | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7456155-B2 | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7429572-B2 | Modified fluorinated nucleoside analogues | PHARMASSET, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7365178-B2 | Acyl-nucleotide probes and methods of their synthesis and use in proteomic analysis | ACTIVX BIOSCIENCES, INC. (US) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | ADAR, FUT5, CSGALNACT1 | LMNA 2839/4885MTOR 4072/4885THRB 4322/4885 |
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, EIF2AK2, HNRNPC | LMNA 2114/4885MTOR 4790/4885THRB 4354/4885 |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | LMNA 1285/4885MTOR 4777/4885THRB 3293/4885 |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | LMNA 503/4885MTOR 3142/4885THRB 3306/4885 |
| US-20230174660-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER | MCL1, BID, BAD | LMNA 1443/4885MTOR 1196/4885THRB 1821/4885 |
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | LMNA 1285/4885MTOR 4777/4885THRB 3293/4885 |
| US-20230399354-A1 | PREPARATION METHOD OF 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDE | UMPS, TYMP, DPYD | LMNA 1634/4885MTOR 979/4885THRB 4250/4885 |
| US-20090131351-A1 | Methods, compositions, and kits for modulating tumor cell proliferation | MKI67, PCNA, HDGF | LMNA 679/4885MTOR 1659/4885THRB 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.